Article Information
History
- January 15, 2017.
Article Versions
- You are currently viewing Version 1 of this article (January 15, 2017 - 21:05).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Joshua B. Radke1+,
- Danielle Worth2,
- Dong-Pyo Hong1,
- Sherri Huang3,
- William J. Sullivan Jr3,
- Emma H. Wilson2 and
- Michael White1,&
- 1Departments of Molecular Medicine & Global Health, University of South Florida, Tampa, FL 33612, USA
- 2Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, California, USA
- 3Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- ↵& Address correspondence to: Michael W. White, Florida Center of Drug Discovery and Innovation, Departments of Molecular Medicine & Global Health, University of South Florida 3720 Spectrum Blvd, Suite 304 Tampa, FL 33612, email: mwhite.usf{at}gmail.com office 813-974-8411, Fax 813-974-0804
Posted January 15, 2017.
Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis
